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a study, which aims to develop clinical criteria for prede-
mentia AD. We also present baseline characteristics of the 
subjects included. The study was part of the multicentre
DESCRIPA project, which is being conducted within the net-
work of the European Alzheimer’s Disease Consortium. 
 Methods: Clinical criteria will be based on a prospective co-
hort study of non-demented subjects older than 55 years 
and referred to a memory clinic. At baseline, a number of 
markers and risk factors for AD were collected, including de-
mographic variables, measures of performance in activities 
of daily living, cognitive, neuroimaging and genetic markers, 
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 Abstract 
 Background: There is an urgent need to identify subjects 
with Alzheimer’s disease (AD) in the predementia phase, but 
validated diagnostic approaches are currently lacking. In this 
paper, we present the background, design and methods of 
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and serum and cerebrospinal fluid markers. Subjects will be 
reassessed annually for 2–3 years, and we will evaluate which 
combination of variables best predicts AD-type dementia at 
follow-up.  Results: Between 2003 and 2005, 881 subjects 
were included from 20 memory clinics. Subjects were on av-
erage 70.3 years old, and had 10.4 years of education. The 
average score on the Mini-Mental State Examination was 
27.4.  Copyright © 2008 S. Karger AG, Basel 
 Introduction 
 Alzheimer’s disease (AD) is one of the most common 
neurodegenerative disorders, with a prevalence rising 
from 0.2% in subjects aged between 55 and 65 years to 
27% in subjects older than 85 years  [1] . According to the 
current diagnostic criteria for AD, the diagnosis can 
only be made when a subject is demented  [2] . There is 
an urgent need to diagnose AD in the predementia phase 
 [3] . This will allow physicians to start interventions that 
may improve cognition, or prevent the progression of 
the disease at an earlier stage than is currently possi-
ble.
 There are as yet no evidence-based criteria for prede-
mentia AD. A large number of predictors or risk factors 
for AD in non-demented subjects have been identified, 
but none of them can individually diagnose predementia 
AD with sufficiently high sensitivity and specificity  [4] . 
There is evidence that a combination of variables may di-
agnose predementia AD with good accuracy  [5–7] . A re-
cent proposal for research criteria for AD suggested using 
a combination of variables to diagnose AD in non-de-
mented subjects  [3] . However, these approaches need to 
be validated and could be improved further.
 In order to investigate which combination of variables 
can best identify subjects with predementia AD, the ‘De-
velopment of Screening Guidelines and Clinical Criteria 
for Predementia AD’ (DESCRIPA) study was set up. The 
study consists of a clinical and population-based part. 
The objective of the clinical part is to develop criteria for 
the diagnosis of predementia AD that can be used in clin-
ical practice. The aim of the population-based part is to 
develop screening guidelines for predementia AD in the 
general population. In this paper, we will describe the 
outline of the clinical part of the DESCRIPA study. We 
will also present baseline characteristics of the subjects 
included in the study.
 Methods 
 General Outline 
 The clinical part of the DESCRIPA study is a prospective co-
hort study. Non-demented subjects with cognitive complaints are 
to be followed for 2–3 years. At baseline, variables were collected 
that could be markers of predementia AD, and we will investigate 
which combination of variables can best predict conversion to 
AD-type dementia at follow-up. The design took into account that 
the study should have sufficient statistical power to test a combi-
nation of predictor variables, and that the criteria for predementia 
AD should allow easy implementation in clinical practice. For the 
latter reason, the data collection closely followed the routine clin-
ical practice in each centre and we allowed variability between 
centres in cognitive tests, clinical rating scales and neuroimaging 
tools, as described below. Centres were selected from the Euro-
pean Alzheimer’s Disease Consortium (EADC), and included 20 
outpatient clinics from 11 European countries. Each of these cen-
tres held a memory clinic specialized in the diagnosis and treat-
ment of memory disorders. The memory clinics were located in 
departments of psychiatry (5 centres), neurology (7 centres), and 
geriatrics (8 centres; see appendix 1 for a list of the participating 
centres). The European Commission funded the study as a con-
certed action within the 5th Framework Programme, and pro-
vided support for coordination, pooling and data analysis from 1 
January 2003 to 1 July 2007, but not for data collection. Subjects 
were enrolled between 1 March 2003 and 1 March 2005. Each 
centre collected a minimal dataset, while other parts of the study 
were optional depending on local clinical practice and local fund-
ing possibilities for data collection.
 Subjects 
 Inclusion and exclusion criteria were chosen in order to select 
a population in which criteria for predementia AD would be most 
useful. Inclusion criteria were new referral to a memory clinic be-
cause of a cognitive complaint and an age of 55 years or over. Ex-
clusion criteria were dementia according to DSM-IV criteria at 
baseline, referral because of a high family risk in otherwise nor-
mal subjects, history of schizophrenia, bipolar disorders or recur-
rent psychotic disorders, and any somatic, psychiatric or neuro-
logical disorder that may have caused the cognitive impairment 
(see appendix 2 for overview of inclusion and exclusion criteria). 
In cases where doubt existed as to whether the cognitive impair-
ment could be attributed to a specific cause, subjects were includ-
ed in the study. All centres enrolled consecutive newly referred 
patients, while 3 centres also retrospectively enrolled subjects that 
were selected from a database.
 Informed Consent Procedure 
 The local Medical Ethical Committee in each centre approved 
the study. Subjects were asked to provide a written informed con-
sent except in 2 centres, in which the study was considered to be 
regular patient care and no specific consent was needed.
 Baseline Assessment 
 At the baseline assessment, data were collected on variables 
that were tested as potential markers of predementia AD, vari-
ables needed for the characterization of subjects and variables 
needed for diagnostic purposes. In 13 centres, the baseline assess-
ment followed routine clinical practice. Four centres extended or 
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changed part of the routine assessment with additional assess-
ments and tests especially for the DESCRIPA study. In 3 centres, 
another study on markers of predementia AD was conducted at 
the same time and the baseline assessment in these centres fol-
lowed the protocol of those studies. All centres collected data on 
demographics, cognitive and non-cognitive symptoms, medical 
history, functional impairment and cognitive performance. In 
addition, a brief physical examination was undertaken. In a sub-
set of centres, data were collected on social and cognitive activi-
ties, neuroimaging, quantitative electroencephalography (Q-
EEG), genetic risk factors, markers in serum and plasma, and 
markers in cerebrospinal fluid (CSF). The baseline assessment in-
cluded the following variables.
 Demographic Variables 
 Demographic data included age, gender, level of education and 
level of occupational achievement.
 Cognitive and Non-Cognitive Symptoms 
 Data were collected on the start of the symptoms, course of the 
symptoms, main complaints and non-cognitive symptoms.
 Family History 
 Data were collected on the number of first-degree and second-
degree relatives with dementia and vascular disorders.
 Medical History 
 Data were collected on conditions that may be associated with 
cognitive impairments such as vascular disorders and vascular 
risk factors, psychiatric disorders, endocrine disorders and severe 
somatic disorders. Data were provided by the patient and/or care-
giver or extracted from medical files if available.
 Medications 
 All medications taken were recorded and classified in a num-
ber of categories.
 Smoking and Alcohol Intake 
 Smoking and alcohol intake measurements were based on the 
interview with patient and caregiver.
 Social and Physical Activities 
 In all but 2 centres, data were collected on cognitive, physical 
and social activities. Cognitive activities were assessed using a 7-
item scale  [8] , physical activities with a 5-item scale, hobbies and 
social activities (e.g. member of a club, volunteer work in church) 
were assessed using structured questions. For each activity, the 
frequency and the average number of hours involved per week was 
rated.
 Physical Examination 
 Data were collected on weight, height, blood pressure, primi-
tive reflexes, extrapyramidal symptoms, gait disturbances and 
other focal neurological signs. Assessments were undertaken ac-
cording to local practice.
 Short Cognitive Screening Tests 
 The Mini-Mental State examination was administered in all 
centres  [9] . A clock-drawing test was done in all but 1 centre.
 Rating Scales for Functional Impairments 
 The effect of cognitive impairment on global functioning was 
measured with the Clinical Dementia Rating Scale (CDR, 18 cen-
tres), the Global Deterioration Scale (GDS, 7 centres) and the 
Cognitive Impairment Rating Scale functional part (CIRS-FP, 17 
centres). The CDR rating was based on a regular clinical interview 
in 11 centres, a structured interview in 4 centres, and either a 
regular or structured interview in 3 centres. The CIRS-FP assess-
es effect of cognitive impairment on daily functioning in the do-
mains of memory, language, executive function/problem solving, 
praxis/visuoconstruction and attention/concentration (see http://
www-np.unimaas.nl/scales/cirs). In order to pool data from cen-
tres that used different scales, a variable of mild functional im-
pairment will be used that reflects a similar degree of impairment 
on each scale. Mild functional impairment on the CDR was de-
fined as a CDR sum of boxes score of at least 1.5 or a score of 1 in 
one of the CDR boxes, on the GDS it was defined as a score of at 
least 3, and on the CIRS-FP as a rating of at least mild impairment 
in the memory domain. The overlap in the definition of mild 
functional impairment according to different scales was good 
[76% for the overlap between CDR and GDS (n = 294,   2 = 39, p  ! 
0.001), 67% for the overlap between CDR and CIRS-FP (n = 688, 
  2 = 68, p  ! 0.001) and 79% for the overlap between GDS and 
CIRS-FP (n = 290,   2 = 56, p  ! 0.001)].
 Scales for Instrumental Activities of Daily Living and 
Activities of Daily Living 
 Instrumental activities of daily living (IADL) or activities of 
daily living (ADL) function was measured with the Blessed De-
mentia Rating Scale (3 centres)  [10] , the Lawton IADL scale (9 
centres)  [11] , the Katz ADL scale (8 centres)  [12] , the Alzheimer’s 
Disease Cooperative Study ADL scale (1 centre)  [13] , the Bayer 
ADL or self-rating Bayer ADL scale (3 centres)  [14] , the Bristol 
ADL scale (1 centre)  [15] or the Barthel Index (2 centres)  [16] . Four 
centres did not use any IADL or ADL scale. In order to pool data 
from centres that used different scales, individual items that as-
sessed the same activities will be pooled, and the number of IADL 
or ADL items impaired will be used as a predictor.
 Scales for Non-Cognitive Symptoms 
 Non-cognitive symptoms were measured with the Neuropsy-
chiatric Inventory (13 centres)  [17] , or the Behave-AD scale (1 cen-
tre)  [18] . Depression severity was measured with the Hamilton 
Depression Rating Scale (HDRS, 5 centres)  [19] , the Montgomery 
Åsberg Rating Scale (MADRS, 4 centres)  [20] , the 15-item Geri-
atric Depression Scale (GDS-15, 7 centres)  [21] , the Cornell Scale 
for Depression in Dementia (Cornell, 4 centres)  [22] or the Centre 
of Epidemiological Studies depression scale (CES-D, 1 centre) 
 [23] . One centre did not use any depression rating scale. In order 
to pool data from different depression scales, we dichotomized 
scores for clinically significant depressive symptomatology on 
each scale. These cut-offs were a score  1 13 on the HDRS  [24] , a 
score  1 14 on the MADRS  [24] , a score  1 7 on the GDS-15  [25] , a 
score  1 10 on the Cornell  [22] and a score  1 24 on the CES-D 
 [26] .
 Cognitive Tests 
 All centres performed cognitive testing but the cognitive tests 
administered varied. In 18 centres, a standardized protocol was 
administered by a neuropsychologist in all patients. In 2 centres, 
 Outline of the DESCRIPA Study Neuroepidemiology 2008;30:254–265 257
tests were administered by a physician as part of the clinical as-
sessment. We selected for each centre a primary test for verbal 
memory, language, attention and executive function, and visuo-
construction, which was identical or similar to tests used in other 
centres. We also selected alternative tests for each primary test in 
case subjects had missing data for the primary test. The primary 
tests selected for each domain are listed in appendix 3. Raw scores 
were converted to age-, education-, and gender-corrected z-scores 
according to normative data of healthy control subjects, and these 
z-scores were used for further analysis. If possible, the same nor-
mative data set was used in each centre (see appendix 3). Neuro-
psychologists were also asked to give a global rating of the cogni-
tive impairment in the domains of memory, language, executive 
function/problem solving, praxis/visuoconstruction, and atten-
tion/concentration using the CIRS-cognitive part (see http://
www-np.unimaas.nl/scales/cirs).
 Neuroimaging 
 MRI was the primary imaging modality in 9 centres, com-
puted tomography (CT) in 9 centres, and single photon emission 
computed tomography (SPECT) in 2 centres. In addition, SPECT 
imaging was performed on a regular basis in 4 other centres as 
well. Neuroimaging markers of predementia AD that were tested 
include medial temporal lobe atrophy and white matter lesions on 
MRI or CT using qualitative rating scales  [27, 28] . On SPECT 
scans, perfusion was investigated as a marker of predementia 
AD.
 Quantitative Electroencephalography 
 Q-EEG was performed in 5 centres. Frequency band analysis 
was used to identify markers of predementia AD.
 Genetic Markers 
 The apolipoprotein E genotype was determined at baseline in 
17 centres. APOE genotype was determined on genomic DNA 
extracted from EDTA anticoagulated blood using the polymerase 
chain reaction technique. In a subset of subjects, DNA was stored 
for future analysis.
 Plasma and Serum Markers 
 Each centre provided data on the routine biochemical and 
haematological laboratory data. In addition, serum and plasma 
were collected and stored at –80 ° C for further analysis in 13 cen-
tres. Planned analyses include measurement of   -amyloid 1–42 
and 1–40 in plasma.
 CSF Markers 
 CSF was collected in 9 centres. Planned analyses include mea-
surement of   -amyloid 1–42, total   , and   phosphorylated at 
threonine 181.
 Follow-Up Assessment 
 In 19 centres, subjects were reassessed annually for 2–3 years. 
The follow-up assessment consisted of a standardized question-
naire about cognitive complaints, non-cognitive symptoms, cur-
rent drug use, medical disorders, physician attendance and hos-
pitalization in the period after the previous assessment. In addi-
tion, the MMSE and clock-drawing test were scored, and the same 
scales for functional impairment and IADL/ADL and cognitive 
tests used at baseline were administered. In case of possible de-
mentia, further diagnostics were performed, including a physical 
examination, assessment of depression severity, and laboratory 
and neuroimaging investigations where appropriate. If a subject 
refused to attend the follow-up assessment or a follow-up assess-
ment could not be arranged, a telephone interview was conducted 
that included the same standardized questionnaire as described 
above, the CDR, and the Telephone Interview for Cognitive Status 
 [29] . In 1 centre, the follow-up was conducted according to rou-
tine clinical practice. Subjects from this centre who were not seen 
at follow-up were contacted 2 years after the baseline assessment 
by telephone, as described above.
 Procedure for Making Diagnoses 
 Dementia was diagnosed according to the DSM-IV criteria 
 [30] , AD was diagnosed according to NINCDS-ADRDA criteria 
 [2] , vascular dementia according to NINCDS-AIREN criteria 
 [31] , Lewy Body dementia according to the McKeith criteria  [32] , 
and fronto-temporal lobe dementia according to the Neary crite-
ria  [33] .
 Clinicians were asked to make the diagnosis at follow-up 
blinded to data collected at baseline, but in some centres clini-
cians had access to baseline cognitive and neuroimaging data. 
Therefore, an endpoint committee, blinded to the baseline assess-
ment data, will review all clinical diagnoses. Each follow-up di-
agnosis will be reviewed by 2 members of the endpoint commit-
tee. If this diagnosis disagrees with the diagnosis provided by the 
centre, other members of the endpoint committee will review the 
case. The final diagnosis will be established by consensus. If
no consensus can be obtained, the subject is considered not de-
mented.
 Outcome Measures 
 The main outcome measure will be conversion to AD-type 
dementia according to the NINCDS-ADRDA criteria of probable 
or possible AD at follow-up. As many subjects with predementia 
AD will not progress to AD-type dementia during the follow-up 
period of 2 years  [34] , a secondary outcome measure will be used 
which includes subjects with AD and non-demented subjects 
with amnestic mild cognitive impairment (MCI) at follow-up. 
These non-demented subjects with amnestic MCI are supposed 
to be at a higher risk of AD at longer follow-up intervals.
 Missing Data 
 In case of missing data, investigators were asked to specify the 
reason why data were missing. Prespecified reasons for missing 
data were patient refusal, technical problems, data not in the cen-
tre’s standard protocol, contraindication for assessment and lack 
of time.
 Analysis and Sample Size Considerations 
 Criteria for predementia AD will be developed in several ways. 
First, a prediction rule will be constructed using logistic regres-
sion models and receiver operating characteristic curves. Vari-
ables will be entered stepwise in the order in which they are col-
lected in the diagnostic work-up, so variables that can be easily 
obtained are entered first (e.g. demographics) while variables that 
are more difficult to obtain (e.g. CSF measures) are entered later. 
To reduce the number of variables, only variables will be entered 
in the analysis that are different between subjects with or without 
probable or possible AD at follow-up on univariate tests at a p 
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value of 0.10 or less. After each step, it will be determined which 
variables in the model can be left out without reducing the overall 
predictive accuracy. The final model will consist of variables that 
are retained in the model after each step. This model will be con-
verted to a prediction rule  [35] .
 Secondly, a non-guided forward stepwise logistic regression 
model will be applied  [36] . In the first step, variables that are dif-
ferent between subjects with or without AD-type dementia at fol-
low-up on univariate tests at a p value of 0.10 or less will be en-
tered. Analysis will be undertaken in different sets of subjects, as 
not all data are available for all subjects. In this way, the shortest 
diagnostic algorithm with a good predictive accuracy (AUC 
 1 0.85) will be established. Thirdly, the Predementia Alzheimer’s 
Disease Scale (PAS) will be scored  [5] . The PAS is a scale, which 
consists of 6 markers of predementia AD. It will be determined 
which cut-off score can best differentiate between subjects with 
or without predementia AD. In addition, the PAS will be adjusted 
or extended with other variables if these variables are predictive 
on univariate tests. In addition, the dataset will be used to cross-
validate other diagnostic algorithms for predementia AD  [3] .
 We planned to enrol 800 subjects, of which it was estimated 
that 20% would progress to AD-type dementia after 2 years. Tak-
ing into account a loss to follow-up of 15%, the number of subjects 
developing AD-type dementia was estimated to be 136. This 
number would be sufficient to allow 14 variables in a multivariate 
analysis, according to the guideline that the number of variables 
in such an analysis should equal the number of subjects in the 
smallest outcome group divided by 10  [37] .
 Results 
 A total of 893 subjects met inclusion and exclusion cri-
teria. Of these, 881 subjects (99%) agreed to participate in 
the study. The number of subjects enrolled was higher 
Table 1. Baseline characteristics
n
Age, years 881 70.387.8
(range 55–92)
Females, n 881 506 (57)
Education, years 881 10.484.2
Setting, n 881
Neurology 385 (44)
Psychiatry 263 (30)
Geriatrics 233 (26)
Referral, n 875
General practitioner 397 (45)
Other physician 188 (21)
Self-referral 253 (29)
Other 37 (4)
Informant present 867
Yes 657 (76)
No 210 (24)
Duration cognitive symptoms, years 846 2.982.7
MMSE, score 873 27.482.2
(range 18–30)
CDR overall score 754
0 47 (6)
0.5 700 (93)
1 7 (0.9)
CDR sum of boxes 755 1.280.92
Z-score learning 829 –0.9081.2
Z-score delayed recall 783 –1.081.3
Z-score TMT A 756 –0.7081.7
Z-score TMT B 742 –0.9682.0
Z-score fluency 836 –0.8481.0
Z-score visuoconstruction 762 0.0881.2
Carrier APOE e4 allele, n 531 217 (41)
Current depression1, n 774 81 (11)
Figures in parentheses are percentages unless otherwise indi-
cated.
MMSE = Mini-Mental State Examination; CDR = Clinical De-
mentia Rating scale; TMT = Trail Making Test; APOE = apolipo-
protein E genotype.
1 Depression refers to clinically significant depressive symp-
tomatology according to cut-off on depression scale (see ‘Meth-
ods’).
Table 2. Prevalence of comorbid disorders according to medical 
history
n
Hypertension 390 (45)
Angina pectoris 96 (11)
Myocardial infarction 52 (6.0)
Carotid stenosis 20 (2.3)
Transient ischaemic attack 48 (5.5)
Cerebral infarction 22 (2.5)
Cerebral bleeding 9 (1.0)
Other atherosclerotic disorder 32 (3.7)
Any atherosclerotic disorder1 187 (21.6)
Hypercholesterolemia 294 (35)
Atrial fibrillation 34 (3.9)
Heart failure 20 (2.3)
Diabetes mellitus 93 (10.7)
Hypothyroid function 83 (9.6)
Hyperthyroid function 29 (3.4)
Depression 181 (20.8)
Chronic obstructive pulmonary disease 39 (4.5)
Figures in parentheses are percentages. Number of subjects 
ranged from 853 (hypercholesterolemia) to 871 (hypertension).  
1 Any atherosclerotic disorder includes angina pectoris, myo-
cardial infarction, carotid stenosis, transient ischaemic attack, ce-
rebral infarction, cerebral bleeding and other atherosclerotic dis-
order.
 Outline of the DESCRIPA Study Neuroepidemiology 2008;30:254–265 259
than planned as we allowed participation of centres that 
joined the EADC after the start of the study. Subjects who 
refused (n = 12) were younger (65.4 vs. 70.3 years, p = 
0.02) and had less years of education (7.7 vs. 10.4 years,
p = 0.02) than those who participated. Gender did not 
differ between the 2 groups. The number of subjects per 
centre was between 10 and 113 (average 44). The majority 
of the subjects were prospectively enrolled (n = 835, 95%). 
The other subjects were retrospectively identified from 
an existing database. A selection of the baseline charac-
teristics is shown in  table 1 . Subjects were on average 70.3 
years old and had 10.4 years of education. About two 
thirds had been referred by a physician (mainly the gen-
eral practitioner), while one third were self-referrals or 
had been referred otherwise; 76% of the subjects came to 
the memory clinic with an informant. Overall cognitive 
impairment as measured with the MMSE was mild, and 
93% of the subjects had a CDR overall score of 0.5. De-
pression at baseline was present in 11% of the subjects.
 Data on medical history were available for 871 (99%) 
of the subjects ( table 2 ). A history of hypertension in 45% 
of the subjects was the most frequently reported comor-
bidity, followed by hypercholesterolemia (35%), an ath-
erosclerotic disorder (22%) and depression (21%). A his-
tory of hypothyroid or hyperthyroid dysfunction was re-
ported in 109 subjects (12%, 3 subjects reported a history 
of both hypo- and hyperthyroid dysfunction), of whom 
73 (67%) received pharmacological treatment at the time 
of the baseline assessment. Diabetes mellitus was report-
ed in 93 subjects (11%), of whom 60 (65%) received phar-
macological treatment at the time of the baseline assess-
ment.
 Cognitive tests had been performed in 862 subjects 
(98%). The reason for no cognitive data was refusal in 3 
subjects, physical limitation in 1 subject, administrative 
error in 1 subject and was unknown in 14 subjects. The 
z-scores of the primary cognitive tests are shown in  ta-
ble 1 . Delayed recall was the most impaired and visuo-
construction the least.
 CT scans were performed in 314 subjects at baseline, 
MRI scans in 435 subjects, SPECT scans in 154 subjects 
and Q-EEG in 198 subjects. CSF was collected in 193 sub-
jects. The results of these assessments will be reported 
separately.
 We noted marked differences in baseline characteris-
tics between the centres. For example, the average age 
ranged between centres from 66 to 74 years, the average 
number of years of education from 7 to 14.1, the average 
MMSE score from 24.4 to 29.1 and the average z-score of 
the delayed recall test from –2.63 to –0.05 ( table 3 ).
 Discussion 
 We described the outline of a study, which aims to de-
velop evidence-based criteria for predementia AD, and 
we presented baseline characteristics of the subjects in-
cluded in the study. The main features of the study design 
Table 3. Baseline characteristics according to centre
Maa. Bre. Ams. KI Mon. The. Mal. Tou. Bar. Gen. Man. Swi. Par. Buc. Kuo. Bat. Nij. Bri. Mun. Ant.
n 59 100 74 55 22 113 27 16 15 50 24 38 27 59 20 10 23 20 19 110
Age 66.3 71.5 70.0 65.8 66.4 67.5 66.9 72.1 73.7 73.9 68.4 71.1 70.0 70.5 70.8 77.1 73.5 72.2 71.8 74.2
Education,
years 11.2 7.5 11.9 11.9 10.8 8.3 12.0 10.8 7.0 8.9 9.3 12.0 13.1 14.1 7.5 11.3 10.2 11.4 9.3 11.0
MMSE 27.7 27.0 27.2 28.1 28.2 27.6 28.7 29.1 27.7 28.8 27.8 29.0 28.2 27.2 24.4 25.7 26.5 25.0 26.3 26.7
CDR-SOB 1.11 1.18 1.97 0.97 0.88 0.85 0.78 0.77 1.0 1.09 1.46 0.55 0.40 1.15 1.40 1.55 1.65 1.65 1.90 n.d.
Learning1 –0.22 –0.87 –0.96 –0.12 –1.54 –0.97 –0.22 –0.38 –0.30 –0.74 –0.66 –0.42 –1.20 –1.59 –1.08 –1.71 –1.95 –1.71 –1.40 –1.1
Delayed
recall1 –0.43 –1.1 –1.08 –0.05 –1.79 –0.67 –0.59 –0.64 –0.71 –1.04 –0.82 n.d. –0.83 –2.10 –1.29 –2.63 –1.92 –2.35 –1.58 –1.1
TMT A1 –0.62 –1.37 –0.29 0.03 –1.0 –1.91 –0.21 –0.35 –1.77 –0.81 –0.59 0.81 –0.33 n.d. –0.40 –0.33 –1.03 –0.94 –0.88 0.17
TMT B1 0.51 –1.51 –0.37 0.09 –0.51 –2.94 0.06 –1.24 –1.94 –1.0 –1.04 0.48 –0.21 n.d. –1.25 –0.73 –1.65 –1.16 –0.95 –1.0
Fluency1 –0.62 –1.0 –0.67 –0.17 –0.84 –0.67 –1.0 –0.68 –0.75 –1.0 –0.57 –0.17 –0.35 –1.78 –0.71 –0.75 –1.06 –1.33 –1.16 –1.0
Visuocon-
struction1 –0.29 –0.07 0.25 0.66 –0.06 –0.39 0.39 0.88 0.74 0.11 –0.40 –0.01 0.39 0.75 –0.20 0.20 0.07 n.d. 0.24 –0.16
All data are means. n.d. = Not done; MMSE = Mini-Mental State Exami-
nation; CDR-SOB = Clinical Dementia Rating scale sum of boxes; TMT = 
Trail Making Test; Maa. = Maastricht; Bre. = Brescia; Ams. = Amsterdam;
KI = Karolinska Institute; Mon. =  Montpellier; The. = Thessaloniki; Mal. = 
Malmö; Tou. = Toulouse; Bar. = Barcelona; Gen. = Genoa; Man. = Mannheim; 
Swi. = Swindon; Par. = Paris; Buc. = Bucharest; Kuo. = Kuopio; Bat. = Bath; 
Nij. = Nijmegen; Bri. = Bristol; Mun. = Munich; Ant. = Antwerp. 
1 Z-score of primary cognitive test (see appendix 3).
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were that we used a combination of variables to develop 
diagnostic criteria, selected subjects who were represen-
tative of the clinical population in which criteria would 
be used, and followed routine clinical practice.
 We selected consecutive newly referred subjects to a 
memory clinic older than 55 years who were not dement-
ed and had no obvious cause of the cognitive impair-
ments. We did not require subjects to have a specific
degree of cognitive or functional impairment, because 
predementia AD can present without cognitive or func-
tional impairments in up to 60% of subjects  [38–40] . 
While broad inclusion criteria will include all subjects 
with predementia AD, the disadvantage is that the con-
version rate to AD-type dementia is lower than if stricter 
inclusion criteria were used. However, the large number 
of subjects included will allow multivariate analysis of 
markers of conversion with sufficient statistical power.
 We followed routine clinical practice in order to gen-
erate criteria that may have a generalized clinical appli-
cability. We noted a substantial variation in scales and 
cognitive tests used between the centres. This variation 
may partly be explained by differences in setting as, for 
example, psychiatrists may prefer other depression rating 
scales than neurologists or geriatricians. In addition, the 
variation may reflect the fact that we included centres 
from different countries, as in some countries tests and 
scales are being used that have been validated and for 
which norms are available in that country. The variation 
in scales and tests is a challenge for the pooling of data. 
For cognitive data, we will use age, education and gender-
corrected z-scores, as it is assumed that the z-score indi-
cates a similar degree of impairment in a cognitive do-
main, even if different tests have been used. In a similar 
way, scores on depression scales and scales for functional 
impairment will be dichotomized according to equiva-
lent cut-offs on each scale. Not all variables could be col-
lected in all centres as part of regular patient care. This 
implies that criteria for predementia AD that would re-
quire MRI imaging or CSF sampling, for example, may 
not be applicable in these settings. We will approach this 
problem by developing a diagnostic algorithm with a 
stepwise approach, so variables that can be easily collect-
ed in clinical practice should be scored first  [5] .
Table 4. Design characteristics of longitudinal studies of non-demented subjects with cognitive impairments in a clinical setting
Observational studies Trials
DESCRIPA PréAL ACCORD ITINAD ADNI Competence
Net Dementias1
ADCS InDDEx Rofe-
coxib1
GAL-
Int11/18
Piracetam1
Inclusion criteria
Mild functional
impairment2 no no no no yes yes yes yes yes yes yes
Test impairment no yes no yes yes yes yes yes yes yes yes
Informant necessary no yes no no yes yes yes yes yes yes yes
Age, years >55 >58 none 50–80 55–90 >50 55–90 55–85 >65 >50 50–90
Exclusion criteria
Disorders causing
cognitive impairment yes yes no yes yes yes yes yes yes yes yes
MMSE cut-off no <25 no ‘abnormal’ <24 <20 <24 no <24 no no
IADL cut-off no yes no yes yes no yes yes yes yes not known
Selection new
consecutive
patient
any
patient
new
consecutive
patient
new
consecutive
patient
any
patient
new
consecutive
patient
any
patient
any
patient
any
patient
any
patient
any
patient
Follow-up length, years 2–3 3 8 2 3 2–3 3 4 4 4 1 
MMSE = Mini-Mental State Examination; PréAL = Prediction for Alz-
heimer’s Disease study [41];  ACCORD = Canadian Collaborative Cohort 
of Related Dementias study [43]; ITINAD = Italian Interdisciplinary Net-
work on Alzheimer’s disease [42]; ADNI = Alzheimer’s Disease Neuroim-
aging Initiative [44]; ADCS = Alzheimer’s Disease Collaborative Study 
[72]; InDDEx = Investigation into Delay to Diagnosis of Alzheimer’s Dis-
ease with Exelon study [73]; GAL-Int11/18 = Galantamine International 
Study 11 and 18 [45]. 
1 Data from the Competence Net were provided by personal communi-
cation; data from the Rofecoxib study were published in [74], data from the 
Piracetam study in [46].
2 Mild functional impairment is an overall Clinical Dementia Rating 
scale score of 0.5 or an equivalent score on another scale. In all studies, 
subjects were required to have cognitive complaints.
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 A number of other large prospective clinical multicen-
tre studies in non-demented subjects with cognitive im-
pairments have been conducted. Some of these studies 
aimed to investigate markers of predementia AD, such as 
the Prediction for Alzheimer’s Disease (PréAL) study in 
France  [41] , the prospective MCI study of the Italian In-
terdisciplinary Network on Alzheimer’s disease (ITI-
NAD;  [42] ), and the Competence Net Dementias study in 
Germany, while other studies were not designed for this 
purpose but still could be used for this such as the Cana-
dian Collaborative Cohort of Related Dementias (AC-
CORD) study in Canada  [43] and the Alzheimer’s Dis-
ease Neuroimaging Initiative (ADNI) in North America 
 [44] . In addition, a number of drug trials in subjects with 
MCI with a follow-up of at least 1 year have been con-
ducted, and these studies may also be used to test markers 
of predementia AD  [7, 39, 45, 46] . A selection of the design 
characteristics of these studies is shown in  table 4 . It can 
be seen that all studies except the ACCORD study used 
more restrictive inclusion criteria than the DESCRIPA 
study. In addition, most studies used additional criteria 
for excluding subjects with possible dementia at baseline, 
for example with an MMSE score or a score on a scale for 
functional impairment. We did not apply such a cut-off 
as we intended to include subjects who were not dement-
ed according to clinical judgment, even though it is pos-
sible that the threshold for diagnosing dementia could 
vary between centres.
 The characteristics of the subjects included in the DE-
SCRIPA study indicates that very mild to mildly impaired 
subjects were included. Vascular, endocrine and psychi-
atric comorbid disorders were common even though we 
excluded subjects in which comorbid disorders were con-
sidered the main cause of the cognitive impairments. We 
will investigate whether these comorbid disorders may 
influence outcome at follow-up. The baseline character-
istics are comparable to those from other prospective 
clinical multicentre studies in non-demented subjects 
with cognitive impairments, as shown in  table 5 .
 We noted substantial differences in baseline charac-
teristics between centres. This may reflect differences in 
referral patterns and settings between the centres. It is 
also likely that as a result the conversion rate to AD will 
vary substantially between centres. We will investigate to 
what extent this variation in baseline characteristics in-
fluences the diagnostic accuracy of criteria of predemen-
tia AD in each centre.
 The study had some limitations. The follow-up period 
of 2–3 years is relatively short as it may take up to 10 years 
before subjects with predementia AD convert into AD-
type dementia  [34, 47, 48] . Using the diagnosis of AD-
type dementia at the 2- or 3-year follow-up as the out-
Table 5. Baseline characteristics of subjects enrolled in clinical prospective studies of non-demented subjects with cognitive impair-
ments
Observational studies Trials
PréAL ACCORD ITINAD ADNI1 Competence
Net Dementias1
ADCS InDDEx Rofecoxib1 GAL-Int11/18 Piracetam1
n 251 466 269 398 997 769      1,018       1,457 2,057 675
Age, years 72.0 65.0 70.3 74.8 67.0 72.9 70.5 74.9 70 68
Education, years – 12.8 7.9 15.7 9.5 14.7 11.1 – – –
Females, % 60 55 57 36 45 46 52 33 55 –
MMSE, score 26.9 27.8 27.1 27.0 27.0 27.3 26.9 27.3 – –
CDR-SOB – – – 1.6 1.6 1.8 1.8 1.4 1.6 –
APOE e4 carrier, % – 40 – 54 46 55 41 35 44 43
MMSE = Mini-Mental State Examination; CDR-SOB = Clini-
cal Dementia Rating scale sum of boxes; APOE = Apolipoprotein 
E genotype; PréAL = Prediction for Alzheimer’s Disease study 
[41]; ACCORD = Canadian Collaborative Cohort of Related De-
mentias study [43]; ITINAD = Italian Interdisciplinary Network 
on Alzheimer’s disease [42]; ADNI = Alzheimer’s Disease Neuro-
imaging Initiative [44]; ADCS = Alzheimer’s Disease Collabora-
tive Study [72]; InDDEx = Investigation into Delay to Diagnosis 
of Alzheimer’s Disease with Exelon study [73]; GAL-Int11/18 = 
Galantamine International Study 11 and 18 [45].
1 ADNI data were exported from the database on 13 November 
2007; data from the Competence Net Dementias were based on an 
export from the database in November 2007; data from the Rofe-
coxib study were published in [74], data from the Piracetam study 
in [46].
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come measure may therefore lead to a false-negative di-
agnosis of predementia AD in a number of subjects. 
Therefore, we will also use a composite outcome measure 
including subjects with AD-type dementia and non-de-
mented subjects with amnestic MCI, who are at a high 
risk of progressing to AD-type dementia at longer follow-
up intervals. We also plan to extend the follow-up period 
to 5 years.
 In subjects who refuse to come for the follow-up, a tele-
phone interview instead of a personal examination will 
be conducted, and this may yield inaccurate information 
on current cognitive status. We will therefore repeat anal-
ysis after exclusion of subjects in which the diagnosis was 
based on a telephone interview. Another limitation is that 
not all variables will have been collected in all centres, 
which limits the power of some of the multivariate analy-
sis. In addition, the different scales and tests used may not 
be equivalent. However, this variability reflects clinical 
practice, and by allowing this the results may be easier to 
implement.
 In conclusion, there is an urgent need to diagnose AD 
before subjects reach a diagnosis of dementia, and the 
DESCRIPA study has been designed to contribute to the 
development of evidence-based criteria for predementia 
AD.
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 Appendix 1 
 List of Participating Centres 
 Department of Psychiatry and Neuropsychology, University 
of Maastricht, The Netherlands [F.R.J. Verhey (PI), P.J. Visser (co-
PI), I. Ramakers].
 LENITEM – Laboratory of Epidemiology and Neuroimaging 
& Telemedicine, IRCCS Centro San Giovanni di Dio Fatebene-
fratelli, Brescia, Italy [G.B. Frisoni (site PI), C. Geroldi, M. Be-
lussi].
 Department of Neurology, Alzheimer Centre, VU Medical 
Centre, Amsterdam, The Netherlands [P. Scheltens (site PI), P.J. 
Visser, L. van de Pol].
 NVS Department, Karolinska Institutet, Karolinska Univer-
sity Hospital, Huddinge, Sweden [L.-O. Wahlund, B. Winblad 
(site PIs), Y. Freund-Levi, V. Jelic, A.-C. Tysen].
 Institute National de la Santé et de la Recherche Medicinale 
INSERM U 888, Montpellier, France [J. Touchon (site PI), F. Por-
tet, M. Messaoudi].
 Aristotle University of Thessaloniki, Memory and Dementia 
Centre, 3rd Department of Neurology, G. Papanicolaore General 
Hospital, Thessaloniki, Greece [M. Tsolaki (site PI), C. Pornari, F. 
Fotiadou].
 Clinical Memory Research Unit, Department of Clinical Sci-
ences Malmö, Lund University, Sweden [L. Minthon (site PI), A. 
Wallin, J. Mauritzson].
 Department of Internal Medicine and Clinical Gerontology, 
Toulouse University Hospital, Toulouse, France [B. Vellas (site 
PI), P.-J. Ousset].
 Fundació ACE, Barcelona, Spain [M. Boada (site PI), M. Buen-
dia].
 Clinical Neurophysiology Unit, Department of Endocrinolog-
ical and Metabolic Sciences, University of Genoa, Genoa, Italy [G. 
Rodriguez (site PI), F. Nobili, N. Girtler, C. De Leo, A. Brugnolo, 
B. Dessi].
 Division of Geriatric Psychiatry, Zentralinstitut für Seelische 
Gesundheit, University of Heidelberg, Mannheim, Germany [L. 
Frölich (site PI), M. Damian, S. Schwarz, M. Syren, C. Knorr, S. 
Thorvaldsen].
 Kingshill Research Centre, Swindon, UK [R. Bullock (site PI), 
A. Marriott].
 Department of Geriatrics, Hopital Broca, Paris, France [A.-S. 
Rigaud (site PI), H. Lenoir].
 ‘Carol Davila’ University of Medicine and Pharmacy, Bucha-
rest, Romania [L. Spiru (site PI), I. Ioancio].
 Department of Neurology, Kuopio University Hospital, Kuo-
pio, Finland [H. Soininen (site PI), T. Pirttilä, co-investigator, M. 
Hallikainen], and Department of Radiology (R. Vanninen).
 Department of Geriatrics, Radboud University Medical Cen-
tre, Nijmegen, The Netherlands [M. Olde-Rikkert (site PI), M. 
Verbeek, R. Esselink, R. Kessels, J. Claassen, R. Melis, M. Ver-
nooij-Dassen].
 The Research Institute for the Care of Older People (RICE), 
Bath, UK [R. Jones (site PI), J. Mann, J. Gifford].
 Department of Care of The Elderly, University of Bristol, 
Frenchay Hospital, Bristol, UK (G. Wilcock, J. Haworth, P. Ke-
hoe).
 Alzheimer Memorial Centre and Geriatric Psychiatry Branch, 
Dementia and Neuroimaging Section Department of Psychiatry, 
Ludwig-Maximilian University, Munich, Germany [H. Hampel 
(site PI), S. Teipel, M. Ewers, K. Bürger, M. Omerovic].
 Institute Born-Bunge, ZNA Middelheim, University of Ant-
werp, Belgium [P.P. de Deyn (site PI), S. Engelborghs, J. Saerens, 
N. Le Bastard, M. Van Buggenhout].
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 Appendix 2 
 Inclusion and Exclusion Criteria 
 Appendix 3 
 Primary Tests for Cognitive Domains 
Number
of centres
Reference for normative data used1
Memory2
RAVLT [49] 9 6 centres [50], 1 centre [51], 1 centre [52],
1 centre locally collected norms 
Word list of CERAD neuropsychological battery [53] 3 2 centres [54], 1 centre [55]
Hopkins Verbal Learning Test [56, 57] 3 2 centres [54], 1 centre locally collected norms
Grober-Buschke Test [58] 2 [59]
ADAS-Cog 10-word list [60] 1 [54]3
Selective Reminding Test [61] 1 Locally collected norms
Logical Memory Test [62] 1 [62]
Language
1-min verbal fluency for animals [63] 17 [63]
2-min verbal fluency for animals [64] 1 [64]
1-min verbal fluency for fruits, animals or car types [65] 1 [65]
1-min fluency for words starting with ‘F’, ‘A’ and ‘S’ [66] 1 Locally collected norms
Attention and executive function
Time to complete Trail Making Test parts A and B [67] 19 18 centres [54], 1 centre [55]
Visuoconstruction
Copy of the Rey-Osterrieth complex figure [68] 13 [69]
Copy CERAD figures [53] 3 2 centres [54], 1 centre [55]
Copy figures from the AMIPB [70] 1 Locally collected norms
Copy figures subtest from the MDB [52] 1 [52]
Cube analysis test of the VOSP [71] 1 Locally collected norms
RAVLT = Rey Auditory Verbal Learning Test; CERAD = Consortium 
to Establish a Registry for AD; AMPIB = Adult Memory and Information 
Processing Battery; MDB = Mental Deterioration Battery; VOSP = Visual 
Object and Space Perception battery.
1 Normative data were used to correct test scores for age, gender or 
education. The same normative data were used in centres that used the 
same tests if the versions of the test were equivalent. Information on nor-
mative data that were collected locally is available on request. 2 From the 
memory tests the learning measure (sum of the words remembered after 
each learning trial) and free delayed recall measure will be used. 3 Because 
no separate norms for the ADAS-Cog word list with 3 learning trials were 
available, norms of the CERAD word list were used.
Inclusion criteria
– New referral to a memory clinic because of cognitive complaints
– Age >55 years
HDRS = Hamilton Depression rating scale; MADRS = Montgomery Åsberg Rating Scale; GDS-15 = 15-item Geriatric Depression Scale; Cornell = Cornell 
Scale for Depression in Dementia; CES-D = Center for Epidemiologic Studies Depression Scale.
Exclusion criteria
– Dementia according to DSM-IV criteria at baseline
– Referral because of a high family risk in otherwise normal subjects
– History of schizophrenia, bipolar disorders or recurrent psychotic 
disorders
– Any somatic, psychiatric or neurological disorder that may have 
caused the cognitive impairment:
– Cerebrovascular accident or strategic infarction with an acute onset 
of the cognitive impairment
– Neurodegenerative diseases such as Parkinson’s disease and 
Huntington’s disease
– Severe head trauma
– Brain tumour
– Well-documented professional intoxication (i.e. long-term solvent 
or heavy-metal exposure)
– Epilepsy
– Brain infections (acute or a sequel of infection)
– Psychotic disorder or delirium
– Severe depression (score on HDRS >20, MADRS >34, GDS-15 >11, 
Cornell >20, CES-D >40 or hospitalization for depression at the 
time of assessment)
– Severe vitamin B6, B12 or thiamine deficiency
– Current severe and prolonged alcohol abuse (on average more than 
35 units per week for more than 1 year) or history of alcohol abuse 
for at least 1 year in the past 5 years
– Use of drugs that invariably cause cognitive impairment (e.g. high-
dose benzodiazepines)
– Any severe somatic comorbidity that might interfere with study 
participation (e.g. terminal cancer)
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